Being that I worked in hospitals for 30 odd years and know first hand how much of an issue diabetes is with tissue decay in the feet, if this research pays off it will be HUGE bucks absolutely HUGE, thus I see it as price sensitive. Yes on the surface I get your point however dig deeper into the significance and future earning potential.
Ann: First Patient enrolled - SynPath Diabetic Foot Ulcer Trial, page-17
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.01 |
Change
-0.030(1.47%) |
Mkt cap ! $1.388B | |||
| Open | High | Low | Value | Volume |
| $2.02 | $2.04 | $1.99 | $2.209M | 1.099M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 12000 | $1.99 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.01 | 4996 | 1 |
View Market Depth
| Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
| PNV (ASX) Chart |